{"database":"biostudies-literature","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":45,"searchCount":0},"additional":{"submitter":["Saravanan S"],"funding":["NIAID NIH HHS"],"pagination":["211-6"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2923210"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["159(2)"],"pubmed_abstract":["Commercial HIV-1 genotypic resistance assays are very expensive, particularly for use in resource-constrained settings like India. Hence a cost effective in-house assay for drug resistance was validated against the standard ViroSeq HIV-1 Genotyping System 2.0 (Celera Diagnostics, CA, USA). A total of 50 samples were used for this evaluation (21 proficiency panels and 29 clinical isolates). Known resistance positions within HIV-1 protease (PR) region (1-99 codons) and HIV-1 reverse-transcriptase (RT) region (1-240 codons) were included. The results were analysed for each codon as follows: (i) concordant; (ii) partially concordant; (iii) indeterminate and (iv) discordant. A total of 2750 codons (55 codons per patient samplex50 samples) associated with drug resistance (1050 PR and 1700 RT) were analysed. For PR, 99% of the codon results were concordant and 1% were partially concordant. For RT, 99% of the codon results were concordant, 0.9% were partially concordant and 0.1% were discordant. No indeterminate results were observed and the results were reproducible. Overall, the in-house assay provided comparable results to those of US FDA approved ViroSeq, which costs about a half of the commercial assay ($ 100 vs. $ 230), making it suitable for resource-limited settings."],"journal":["Journal of virological methods"],"pubmed_title":["Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method."],"pmcid":["PMC2923210"],"funding_grant_id":["R01 AI066922-03","R01 AI066922"],"pubmed_authors":["Saravanan S","Solomon S","Kantor R","Balakrishanan P","Vidya M","Kumarasamy N","Katzenstein D","Balakrishnan P","Ramratnam B","Solomon SS","Mayer KH"],"view_count":["45"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method.","description":"Commercial HIV-1 genotypic resistance assays are very expensive, particularly for use in resource-constrained settings like India. Hence a cost effective in-house assay for drug resistance was validated against the standard ViroSeq HIV-1 Genotyping System 2.0 (Celera Diagnostics, CA, USA). A total of 50 samples were used for this evaluation (21 proficiency panels and 29 clinical isolates). Known resistance positions within HIV-1 protease (PR) region (1-99 codons) and HIV-1 reverse-transcriptase (RT) region (1-240 codons) were included. The results were analysed for each codon as follows: (i) concordant; (ii) partially concordant; (iii) indeterminate and (iv) discordant. A total of 2750 codons (55 codons per patient samplex50 samples) associated with drug resistance (1050 PR and 1700 RT) were analysed. For PR, 99% of the codon results were concordant and 1% were partially concordant. For RT, 99% of the codon results were concordant, 0.9% were partially concordant and 0.1% were discordant. No indeterminate results were observed and the results were reproducible. Overall, the in-house assay provided comparable results to those of US FDA approved ViroSeq, which costs about a half of the commercial assay ($ 100 vs. $ 230), making it suitable for resource-limited settings.","dates":{"release":"2009-01-01T00:00:00Z","publication":"2009 Aug","modification":"2024-11-08T13:30:38.089Z","creation":"2019-06-06T22:17:55Z"},"accession":"S-EPMC2923210","cross_references":{"pubmed":["19490976"],"doi":["10.1016/j.jviromet.2009.03.021"]}}